Education
About Us
Working with TipRanks
Follow Us
Ra Capital Management, Llc Insider Profile
46 Followers
Ra Capital Management, Llc, Former 10% Owner. See FN(1)(6) at Achillion Pharmaceuticals, holds 5.40M shares in Vor Biopharma (Ticker: VOR), holds 11.29M shares in Climb Bio (Ticker: CLYM), holds 6.05M shares in Fulcrum Therapeutics (Ticker: FULC).
Ra Capital Management, Llc Achillion Pharmaceuticals (~ACHN)Former 10% Owner. See FN(1)(6)
Achillion Pharmaceuticals (~ACHN)
Former 10% Owner. See FN(1)(6)
Ranked #4,896 out of 105,390 Corporate Insiders
Profitable Transactions
55 out of 152 Profitable Transactions
Average Return
+8.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Ra Capital Management, Llc's holdings
Insider Roles
Roles that Ra Capital Management, Llc holds in companies
Most Profitable Insider Trade
Stock:
89bio
(ETNB)
(ETNB)
Rating:Informative Buy
Date:Jul 06, 2022 - Jul 06, 2023
Return:+497.40%
The most profitable trade made by Ra Capital Management, Llc
Ra Capital Management, Llc's Trading History
Achillion Pharmaceuticals
Jan 20, 2015
―
Informative Buy
7.83M
$32.56M
Aclaris Therapeutics
Sep 19, 2016
Ten Percent Owner
Informative Sell
12.71M
$6.60M
KalVista Pharmaceuticals
Oct 16, 2017
Director
Informative Buy
7.22M
$9.00M
Wave Life Sciences
Nov 14, 2025
Director, Ten Percent Owner
Informative Buy
6.68K
$291.34M
Ra Pharmaceuticals
Apr 03, 2020
―
Uninformative Sell
233.20M
$0.00
Eidos Therapeutics
Jun 22, 2018
―
Uninformative Buy
―
$264.30M
Arvinas Holding Company
Oct 03, 2018
Former 10% Owner
Uninformative Buy
―
$36.66M
KALA BIO
May 26, 2022
Ten Percent Owner
Informative Sell
362.05K
$4.38M
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$617.51M
scPharmaceuticals
Mar 16, 2021
―
Informative Sell
1.06M
$15.46M
Satsuma Pharmaceuticals
Jun 12, 2023
―
Uninformative Sell
―
$0.00
89bio
Feb 03, 2025
―
Informative Buy
50.00M
$295.16M
Synthorx
Jan 24, 2020
―
Uninformative Sell
661.27M
$0.00
Enliven Therapeutics
Feb 27, 2023
Former 10% owner
Uninformative Buy
―
$35.81M
Phathom Pharmaceuticals
Mar 15, 2021
Ten Percent Owner
Informative Sell
31.06M
$54.61M
Verastem
Jun 29, 2020
Ten Percent Owner
Informative Sell
2.22M
$125.26M
Forma Therapeutics Holdings
Oct 14, 2022
―
Uninformative Sell
―
$0.00
Rhythm Pharmaceuticals
Dec 04, 2020
Former 10% Owner
Informative Sell
7.03M
$489.03M
AKOUOS
Jul 02, 2020
―
Uninformative Buy
―
$30.32M
Nkarta
Mar 29, 2024
Director, Ten Percent Owner
Informative Buy
30.00M
$19.34M
Pandion Therapeutics
Jul 22, 2020
―
Uninformative Buy
―
$106.29M
Inozyme Pharma
Jul 28, 2020
―
Uninformative Buy
―
$8.01M
iTeos Therapeutics
May 14, 2024
―
Uninformative Sell
―
$35.70M
Inhibrx
Aug 24, 2020
―
Uninformative Buy
―
$72.62M
TG Therapeutics
Sep 11, 2020
Ten Percent Owner
Informative Sell
4.09M
$391.27M
Dyne Therapeutics
Sep 23, 2020
Ten Percent Owner
Uninformative Buy
―
$55.68M
PMV Pharmaceuticals
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
―
$2.12M
Vaxcyte
Oct 01, 2020
Ten Percent Owner
Informative Sell
11.24M
$245.27M
Orchard Therapeutics
Nov 06, 2020
―
Informative Buy
3.56M
$165.01M
Iterum Therapeutics
Feb 08, 2021
Ten Percent Owner
Uninformative Buy
―
$4.31M
Vor Biopharma
Dec 19, 2025
Director, Ten Percent Owner
Uninformative Sell
50.00M
$67.08M
Solid Biosciences
Jan 12, 2024
Ten Percent Owner
Informative Buy
5.00M
$25.55M
Werewolf Therapeutics
May 14, 2025
Director, Ten Percent Owner
Informative Buy
487.19K
$4.58M
Janux Therapeutics Inc
Jun 13, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$154.39M
Jade Biosciences
Apr 30, 2025
Ten Percent Owner
Uninformative Buy
―
$22.56M
Acumen Pharmaceuticals
Jun 05, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$32.13M
POINT Biopharma Global
Jun 30, 2021
―
Informative Buy
2.09M
$13.73M
Cytek Biosciences
Mar 16, 2022
Director, Ten Percent Owner
Uninformative Buy
7.19M
$66.24M
Icosavax
Feb 20, 2024
―
Uninformative Sell
―
$0.00
Climb Bio
Dec 15, 2025
Director, Ten Percent Owner
Informative Buy
754.74K
$48.34M
Tyra Bioscience
Jun 16, 2025
Director, Ten Percent Owner
Informative Buy
1.66M
$311.19M
Dice Therapeutics
Aug 09, 2023
―
Uninformative Sell
―
$0.00
AN2 Therapeutics, Inc.
Aug 13, 2024
Ten Percent Owner
Informative Sell
3.81M
$336.96K
PepGen Inc.
Sep 30, 2025
Director, Ten Percent Owner
Informative Buy
30.00M
$108.75M
ARS Pharmaceuticals
Mar 27, 2024
Director, Ten Percent Owner
Informative Buy
13.29M
$113.93M
Fulcrum Therapeutics
Dec 10, 2025
Ten Percent Owner
Informative Sell
58.38M
$74.34M
Mineralys Therapeutics, Inc.
Sep 08, 2025
Director
Informative Buy
30.00M
$269.73M
Black Diamond Therapeutics
Jul 07, 2023
Director
Informative Buy
4.68M
$8.96M
LENZ Therapeutics
Mar 25, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$25.01M
Boundless Bio Inc.
Apr 04, 2024
Ten Percent Owner
Uninformative Buy
―
$360.93K
Acrivon Therapeutics, Inc.
Apr 15, 2024
Director, Ten Percent Owner
Uninformative Buy
30.00M
$18.02M
Cidara Therapeutics
Jun 30, 2025
Director, Ten Percent Owner
Informative Buy
100.00M
$743.11M
Artiva Biotherapeutics, Inc.
Jul 24, 2024
Director, Ten Percent Owner
Uninformative Buy
4.71M
$3.92M
Bicara Therapeutics Inc.
Sep 18, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$46.69M
Septerna, Inc.
Oct 30, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$43.54M
4D Molecular Therapeutics
Dec 10, 2024
Ten Percent Owner
Uninformative Sell
―
$39.61M
Sionna Therapeutics, Inc.
Nov 24, 2025
Director, Ten Percent Owner
Informative Sell
1.20M
$6.74M
Evommune, Inc.
Nov 12, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$14.31M
Sangamo Biosciences
Feb 18, 2015
Former 10% Owner
Informative Buy
―
$2.46M
Biospecifics Technologies
Feb 26, 2010
―
Informative Sell
288.30K
$55.46M
Dicerna Pharma
Feb 05, 2014
―
Informative Buy
15.00M
$193.93M
Sequenom
―
―
―
$27.21M
Curis
―
Ten Percent Owner
―
$6.69M
Derma Sciences
Jan 13, 2014
―
Informative Sell
3.55M
$11.86M
Aradigm
―
―
―
$49.74K
List of latest transactions for each holding click on a transaction to see Ra Capital Management, Llc's performance on stock
You May Also Like
Ra Capital Management, Llc insider profile FAQ
What is the percentage of profitable transactions made by Ra Capital Management, Llc?
The percentage of profitable transactions made by Ra Capital Management, Llc is 36%.
What is the average return per transaction made by Ra Capital Management, Llc?
The average return per transaction made by Ra Capital Management, Llc is 8.40%.
What stocks does Ra Capital Management, Llc hold?
Ra Capital Management, Llc holds: ~ACHN, ACRS, KALV, WVE, RARX, EIDX, ARVN, KALA, ~THOR, SCPH, STSA, ETNB, THOR, ELVN, PHAT, VSTM, FMTX, RYTM, AKUS, NKTX, PAND, INZY, ITOS, ~INBX, TGTX, DYN, PMVP, PCVX, ORTX, ITRM, VOR, SLDB, HOWL, JANX, JBIO, ABOS, PNT, CTKB, ICVX, CLYM, TYRA, DICE, ANTX, PEPG, SPRY, FULC, MLYS, BDTX, LENZ, BOLD, ACRV, CDTX, ARTV, BCAX, SEPN, FDMT, SION, EVMN, SGMO, BSTC, DRNA, SQNM, CRIS, DSCI, ARDMQ stocks.
What was Ra Capital Management, Llc’s latest transaction?
Ra Capital Management, Llc latest transaction was an Uninformative Sell of $50.00M.
What was Ra Capital Management, Llc's most profitable transaction?
Ra Capital Management, Llc’s most profitable transaction was an Informative Buy of ETNB stock on July 6, 2022. The return on the trade was 497.40%.
What is Ra Capital Management, Llc's role in Achillion Pharmaceuticals?
Ra Capital Management, Llc's role in Achillion Pharmaceuticals is Former 10% Owner. See FN(1)(6).
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.